AHA 2020 | POLYPILL: One Pill Plus Aspirin to Treat Everything

Using only one compressed tablet or pill with a fixed combination of statins, angiotensin-converting enzyme inhibitors, beta-blockers, and diuretics significantly lowered cardiovascular risk in a large population without previous events (primary prevention). However, it presented an intermediate risk of cardiovascular disease onset.

The TIPS-3 (The International Polycap Study 3) study had a 2-by-2-by-2 factorial design, and was partly presented at the American Heart Association (AHA) 2020 Congress.

Adding 75 mg of aspirin to the poypill diminished the relative risk of the study’s primary endpoint (a composite of death, infarction, stroke, sudden death, heart failure, or revascularization) by 31% compared to a double placebo. In absolute terms, this reduction is equal to 1.7%.

The polypill (without aspirin added) showed a borderline statistically significant benefit compared with a placebo. After 5 years of follow-up, the primary endpoint was reached in 4.4% of the polypill arm vs. 5.5% of the placebo arm (hazard ratio: 0.79; 95% confidence interval: 0.63-1.00).

The polypill included 40 mg of simvastatin, 100 mg of atenolol, 10 mg of ramipril, and 25 mg of hydrochlorothiazide.


Read also: The Most Read Scientific Articles in Interventional Cardiology.


Not all physicians were sold on this idea. Many considered the simvastatin dose as excessive, given its possible subsequent pharmacological interactions. The same consideration was applied, even more, to the 100 mg of atenolol in patients with no-known heart disease. 

Polypill

Original Title: Polypill with or without aspirin in persons without cardiovascular disease.

Reference: Yusuf S et al. Presentado en el congreso AHA 2020 y publicado simultánemante en N Engl J Med 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...